Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Post-acquisition processing confounds in brain volumetric quantification of white matter hyperintensities.

Bahrani AA, Al-Janabi OM, Abner EL, Bardach SH, Kryscio RJ, Wilcock DM, Smith CD, Jicha GA.

J Neurosci Methods. 2019 Nov 1;327:108391. doi: 10.1016/j.jneumeth.2019.108391. Epub 2019 Aug 10.

PMID:
31408649
2.

Blood Flow Deficits and Cerebrovascular Changes in a Dietary Model of Hyperhomocysteinemia.

Braun DJ, Abner E, Bakshi V, Goulding DS, Grau EM, Lin AL, Norris CM, Sudduth TL, Webster SJ, Wilcock DM, Van Eldik LJ.

ASN Neuro. 2019 Jan-Dec;11:1759091419865788. doi: 10.1177/1759091419865788. No abstract available.

3.

White Matter Hyperintensity Regression: Comparison of Brain Atrophy and Cognitive Profiles with Progression and Stable Groups.

Al-Janabi OM, Bauer CE, Goldstein LB, Murphy RR, Bahrani AA, Smith CD, Wilcock DM, Gold BT, Jicha GA.

Brain Sci. 2019 Jul 19;9(7). pii: E170. doi: 10.3390/brainsci9070170.

4.

Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival.

Ferguson J, Wilcock DJ, McEntegart S, Badrock AP, Levesque M, Dummer R, Wellbrock C, Smith MP.

Pigment Cell Melanoma Res. 2019 Jul 19. doi: 10.1111/pcmr.12812. [Epub ahead of print]

PMID:
31323160
5.

Genetic knockout of myosin light chain kinase (MLCK210) prevents cerebral microhemorrhages and attenuates neuroinflammation in a mouse model of vascular cognitive impairment and dementia.

Braun DJ, Bachstetter AD, Sudduth TL, Wilcock DM, Watterson DM, Van Eldik LJ.

Geroscience. 2019 May 19. doi: 10.1007/s11357-019-00072-4. [Epub ahead of print]

PMID:
31104189
6.

White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities.

Alber J, Alladi S, Bae HJ, Barton DA, Beckett LA, Bell JM, Berman SE, Biessels GJ, Black SE, Bos I, Bowman GL, Brai E, Brickman AM, Callahan BL, Corriveau RA, Fossati S, Gottesman RF, Gustafson DR, Hachinski V, Hayden KM, Helman AM, Hughes TM, Isaacs JD, Jefferson AL, Johnson SC, Kapasi A, Kern S, Kwon JC, Kukolja J, Lee A, Lockhart SN, Murray A, Osborn KE, Power MC, Price BR, Rhodius-Meester HFM, Rondeau JA, Rosen AC, Rosene DL, Schneider JA, Scholtzova H, Shaaban CE, Silva NCBS, Snyder HM, Swardfager W, Troen AM, van Veluw SJ, Vemuri P, Wallin A, Wellington C, Wilcock DM, Xie SX, Hainsworth AH.

Alzheimers Dement (N Y). 2019 Apr 9;5:107-117. doi: 10.1016/j.trci.2019.02.001. eCollection 2019. Review.

7.

The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy.

Seed RI, Taurozzi AJ, Wilcock DJ, Nappo G, Erb HHH, Read ML, Gurney M, Archer LK, Ito S, Rumsby MG, Petrie JL, Clayton A, Maitland NJ, Collins AT.

Sci Rep. 2019 Mar 26;9(1):5120. doi: 10.1038/s41598-019-41379-8.

8.

Cerebrovascular Smooth Muscle Cells as the Drivers of Intramural Periarterial Drainage of the Brain.

Aldea R, Weller RO, Wilcock DM, Carare RO, Richardson G.

Front Aging Neurosci. 2019 Jan 23;11:1. doi: 10.3389/fnagi.2019.00001. eCollection 2019.

9.

Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models.

Lourenco MV, Frozza RL, de Freitas GB, Zhang H, Kincheski GC, Ribeiro FC, Gonçalves RA, Clarke JR, Beckman D, Staniszewski A, Berman H, Guerra LA, Forny-Germano L, Meier S, Wilcock DM, de Souza JM, Alves-Leon S, Prado VF, Prado MAM, Abisambra JF, Tovar-Moll F, Mattos P, Arancio O, Ferreira ST, De Felice FG.

Nat Med. 2019 Jan;25(1):165-175. doi: 10.1038/s41591-018-0275-4. Epub 2019 Jan 7.

10.

Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, Bahar-Fuchs A, Bell J, Bowman GL, Brickman AM, Chételat G, Ciro C, Cohen AD, Dilworth-Anderson P, Dodge HH, Dreux S, Edland S, Esbensen A, Evered L, Ewers M, Fargo KN, Fortea J, Gonzalez H, Gustafson DR, Head E, Hendrix JA, Hofer SM, Johnson LA, Jutten R, Kilborn K, Lanctôt KL, Manly JJ, Martins RN, Mielke MM, Morris MC, Murray ME, Oh ES, Parra MA, Rissman RA, Roe CM, Santos OA, Scarmeas N, Schneider LS, Schupf N, Sikkes S, Snyder HM, Sohrabi HR, Stern Y, Strydom A, Tang Y, Terrera GM, Teunissen C, Melo van Lent D, Weinborn M, Wesselman L, Wilcock DM, Zetterberg H, O'Bryant SE; International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association.

Alzheimers Dement. 2019 Feb;15(2):292-312. doi: 10.1016/j.jalz.2018.09.009. Epub 2018 Dec 13.

11.

Hyperhomocysteinemia as a Risk Factor for Vascular Contributions to Cognitive Impairment and Dementia.

Price BR, Wilcock DM, Weekman EM.

Front Aging Neurosci. 2018 Oct 31;10:350. doi: 10.3389/fnagi.2018.00350. eCollection 2018. Review.

12.

Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-β1-42 and Hypertension.

Al-Janabi OM, Brown CA, Bahrani AA, Abner EL, Barber JM, Gold BT, Goldstein LB, Murphy RR, Nelson PT, Johnson NF, Shaw LM, Smith CD, Trojanowski JQ, Wilcock DM, Jicha GA.

J Alzheimers Dis. 2018;66(3):1095-1104. doi: 10.3233/JAD-180663.

13.

Diffuse Amyloid-β Plaques, Neurofibrillary Tangles, and the Impact of APOE in Elderly Persons' Brains Lacking Neuritic Amyloid Plaques.

Abner EL, Neltner JH, Jicha GA, Patel E, Anderson SL, Wilcock DM, Van Eldik LJ, Nelson PT.

J Alzheimers Dis. 2018;64(4):1307-1324. doi: 10.3233/JAD-180514.

14.

Mechanical thrombectomy in acute ischaemic stroke: a review of the different techniques.

Leung V, Sastry A, Srivastava S, Wilcock D, Parrott A, Nayak S.

Clin Radiol. 2018 May;73(5):428-438. doi: 10.1016/j.crad.2017.10.022. Epub 2018 Jan 9. Review.

PMID:
29329730
15.

Global Cerebral Atrophy Detected by Routine Imaging: Relationship with Age, Hippocampal Atrophy, and White Matter Hyperintensities.

Al-Janabi OM, Panuganti P, Abner EL, Bahrani AA, Murphy R, Bardach SH, Caban-Holt A, Nelson PT, Gold BT, Smith CD, Wilcock DM, Jicha GA.

J Neuroimaging. 2018 May;28(3):301-306. doi: 10.1111/jon.12494. Epub 2018 Jan 5.

16.

An emerging role of astrocytes in vascular contributions to cognitive impairment and dementia.

Price BR, Norris CM, Sompol P, Wilcock DM.

J Neurochem. 2018 Mar;144(5):644-650. doi: 10.1111/jnc.14273. Epub 2018 Jan 22. Review.

17.

Hyperhomocysteinemia-Induced Gene Expression Changes in the Cell Types of the Brain.

Weekman EM, Woolums AE, Sudduth TL, Wilcock DM.

ASN Neuro. 2017 Nov-Dec;9(6):1759091417742296. doi: 10.1177/1759091417742296.

18.

The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases.

Nelson PT, Abner EL, Patel E, Anderson S, Wilcock DM, Kryscio RJ, Van Eldik LJ, Jicha GA, Gal Z, Nelson RS, Nelson BG, Gal J, Azam MT, Fardo DW, Cykowski MD.

J Neuropathol Exp Neurol. 2018 Jan 1;77(1):2-20. doi: 10.1093/jnen/nlx099. Review.

19.

Specific Immunoglobulin (Ig) G Reference Intervals for Common Food, Insect, and Mold Allergens.

Martins TB, Bandhauer ME, Wilcock DM, Hill HR, Slev PR.

Ann Clin Lab Sci. 2016 Dec;46(6):635-638.

PMID:
27993877
20.

Time-course of glial changes in the hyperhomocysteinemia model of vascular cognitive impairment and dementia (VCID).

Sudduth TL, Weekman EM, Price BR, Gooch JL, Woolums A, Norris CM, Wilcock DM.

Neuroscience. 2017 Jan 26;341:42-51. doi: 10.1016/j.neuroscience.2016.11.024. Epub 2016 Nov 25.

21.

Aβ vaccination in combination with behavioral enrichment in aged beagles: effects on cognition, Aβ, and microhemorrhages.

Davis PR, Giannini G, Rudolph K, Calloway N, Royer CM, Beckett TL, Murphy MP, Bresch F, Pagani D, Platt T, Wang X, Donovan AS, Sudduth TL, Lou W, Abner E, Kryscio R, Wilcock DM, Barrett EG, Head E.

Neurobiol Aging. 2017 Jan;49:86-99. doi: 10.1016/j.neurobiolaging.2016.09.007. Epub 2016 Sep 26.

22.

Reduced Efficacy of Anti-Aβ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity.

Weekman EM, Sudduth TL, Caverly CN, Kopper TJ, Phillips OW, Powell DK, Wilcock DM.

J Neurosci. 2016 Sep 21;36(38):9896-907. doi: 10.1523/JNEUROSCI.1762-16.2016.

23.

(1)H-MRS metabolites in adults with Down syndrome: Effects of dementia.

Lin AL, Powell D, Caban-Holt A, Jicha G, Robertson W, Gold BT, Davis R, Abner E, Wilcock DM, Schmitt FA, Head E.

Neuroimage Clin. 2016 Jun 2;11:728-735. doi: 10.1016/j.nicl.2016.06.001. eCollection 2016.

24.

Vascular Contributions to Cognitive Impairment and Dementia: Topical Review of Animal Models.

Madigan JB, Wilcock DM, Hainsworth AH.

Stroke. 2016 Jul;47(7):1953-9. doi: 10.1161/STROKEAHA.116.012066. Epub 2016 Jun 14. Review. No abstract available.

25.

The roles of inflammation and immune mechanisms in Alzheimer's disease.

Van Eldik LJ, Carrillo MC, Cole PE, Feuerbach D, Greenberg BD, Hendrix JA, Kennedy M, Kozauer N, Margolin RA, Molinuevo JL, Mueller R, Ransohoff RM, Wilcock DM, Bain L, Bales K.

Alzheimers Dement (N Y). 2016 May 30;2(2):99-109. doi: 10.1016/j.trci.2016.05.001. eCollection 2016 Jun. Review.

26.

Calcineurin proteolysis in astrocytes: Implications for impaired synaptic function.

Pleiss MM, Sompol P, Kraner SD, Abdul HM, Furman JL, Guttmann RP, Wilcock DM, Nelson PT, Norris CM.

Biochim Biophys Acta. 2016 Sep;1862(9):1521-32. doi: 10.1016/j.bbadis.2016.05.007. Epub 2016 May 20.

27.

Animal Models of Vascular Cognitive Impairment and Dementia (VCID).

Gooch J, Wilcock DM.

Cell Mol Neurobiol. 2016 Mar;36(2):233-9. doi: 10.1007/s10571-015-0286-3. Epub 2016 Mar 17. Review.

PMID:
26988696
28.

Vascular contributions to cognitive impairment and dementia (VCID).

Murphy MP, Corriveau RA, Wilcock DM.

Biochim Biophys Acta. 2016 May;1862(5):857-9. doi: 10.1016/j.bbadis.2016.02.010. Epub 2016 Feb 26. No abstract available.

29.

Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID).

Hainsworth AH, Yeo NE, Weekman EM, Wilcock DM.

Biochim Biophys Acta. 2016 May;1862(5):1008-17. doi: 10.1016/j.bbadis.2015.11.015. Epub 2015 Dec 9. Review.

30.

Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Head E, Lott IT, Wilcock DM, Lemere CA.

Curr Alzheimer Res. 2016;13(1):18-29. Review.

31.

Matrix Metalloproteinase in Blood-Brain Barrier Breakdown in Dementia.

Weekman EM, Wilcock DM.

J Alzheimers Dis. 2016;49(4):893-903. doi: 10.3233/JAD-150759. Review.

PMID:
26599057
32.

Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Wilcock DM, Schmitt FA, Head E.

Biochim Biophys Acta. 2016 May;1862(5):909-14. doi: 10.1016/j.bbadis.2015.11.007. Epub 2015 Nov 26. Review.

33.

Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease.

Wilcock DM, Hurban J, Helman AM, Sudduth TL, McCarty KL, Beckett TL, Ferrell JC, Murphy MP, Abner EL, Schmitt FA, Head E.

Neurobiol Aging. 2015 Sep;36(9):2468-74. doi: 10.1016/j.neurobiolaging.2015.05.016. Epub 2015 May 30.

34.

Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid-β using BV2 microglial cells and APP/PS1 transgenic mice.

Latta CH, Sudduth TL, Weekman EM, Brothers HM, Abner EL, Popa GJ, Mendenhall MD, Gonzalez-Oregon F, Braun K, Wilcock DM.

J Neuroinflammation. 2015 Mar 4;12:41. doi: 10.1186/s12974-015-0243-6.

35.

Vascular contributions to cognitive impairment and dementia including Alzheimer's disease.

Snyder HM, Corriveau RA, Craft S, Faber JE, Greenberg SM, Knopman D, Lamb BT, Montine TJ, Nedergaard M, Schaffer CB, Schneider JA, Wellington C, Wilcock DM, Zipfel GJ, Zlokovic B, Bain LJ, Bosetti F, Galis ZS, Koroshetz W, Carrillo MC.

Alzheimers Dement. 2015 Jun;11(6):710-7. doi: 10.1016/j.jalz.2014.10.008. Epub 2014 Dec 12. Review.

36.

Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy.

Latta CH, Brothers HM, Wilcock DM.

Neuroscience. 2015 Aug 27;302:103-11. doi: 10.1016/j.neuroscience.2014.09.061. Epub 2014 Oct 5. Review.

37.

Transition from an M1 to a mixed neuroinflammatory phenotype increases amyloid deposition in APP/PS1 transgenic mice.

Weekman EM, Sudduth TL, Abner EL, Popa GJ, Mendenhall MD, Brothers HM, Braun K, Greenstein A, Wilcock DM.

J Neuroinflammation. 2014 Jul 25;11:127. doi: 10.1186/1742-2094-11-127.

38.

mNos2 deletion and human NOS2 replacement in Alzheimer disease models.

Colton CA, Wilson JG, Everhart A, Wilcock DM, Puoliväli J, Heikkinen T, Oksman J, Jääskeläinen O, Lehtimäki K, Laitinen T, Vartiainen N, Vitek MP.

J Neuropathol Exp Neurol. 2014 Aug;73(8):752-69. doi: 10.1097/NEN.0000000000000094.

39.

β-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice.

Sudduth TL, Weekman EM, Brothers HM, Braun K, Wilcock DM.

Alzheimers Res Ther. 2014 Jun 9;6(3):32. doi: 10.1186/alzrt262. eCollection 2014.

40.

Obesity and diabetes cause cognitive dysfunction in the absence of accelerated β-amyloid deposition in a novel murine model of mixed or vascular dementia.

Niedowicz DM, Reeves VL, Platt TL, Kohler K, Beckett TL, Powell DK, Lee TL, Sexton TR, Song ES, Brewer LD, Latimer CS, Kraner SD, Larson KL, Ozcan S, Norris CM, Hersh LB, Porter NM, Wilcock DM, Murphy MP.

Acta Neuropathol Commun. 2014 Jun 10;2:64. doi: 10.1186/2051-5960-2-64.

41.

Improved glucose metabolism in vitro and in vivo by an allosteric monoclonal antibody that increases insulin receptor binding affinity.

Corbin JA, Bhaskar V, Goldfine ID, Bedinger DH, Lau A, Michelson K, Gross LM, Maddux BA, Kuan HF, Tran C, Lao L, Handa M, Watson SR, Narasimha AJ, Zhu S, Levy R, Webster L, Wijesuriya SD, Liu N, Wu X, Chemla-Vogel D, Lee SR, Wong S, Wilcock D, White ML.

PLoS One. 2014 Feb 12;9(2):e88684. doi: 10.1371/journal.pone.0088684. eCollection 2014.

42.

Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: a potential new approach for the treatment of hyperinsulinemic hypoglycemia.

Corbin JA, Bhaskar V, Goldfine ID, Issafras H, Bedinger DH, Lau A, Michelson K, Gross LM, Maddux BA, Kuan HF, Tran C, Lao L, Handa M, Watson SR, Narasimha AJ, Zhu S, Levy R, Webster L, Wijesuriya SD, Liu N, Wu X, Chemla-Vogel D, Lee SR, Wong S, Wilcock D, Rubin P, White ML.

MAbs. 2014 Jan-Feb;6(1):262-72. doi: 10.4161/mabs.26871.

43.

Neuroinflammatory phenotypes and their roles in Alzheimer's disease.

Wilcock DM.

Neurodegener Dis. 2014;13(2-3):183-5. doi: 10.1159/000354228. Epub 2013 Sep 6.

PMID:
24021538
44.

Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis.

Wilcock DM, Griffin WS.

J Neuroinflammation. 2013 Jul 16;10:84. doi: 10.1186/1742-2094-10-84. Review.

45.

APOE-ε2 and APOE-ε4 correlate with increased amyloid accumulation in cerebral vasculature.

Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, Rebeck GW.

J Neuropathol Exp Neurol. 2013 Jul;72(7):708-15. doi: 10.1097/NEN.0b013e31829a25b9.

46.
47.

Neurological picture. Herpes encephalitis complicated by cerebral haemorrhage.

Lo WB, Wilcock DJ, Carey M, Albanese E.

J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1404-6. doi: 10.1136/jnnp-2013-305552. Epub 2013 May 28. No abstract available.

PMID:
23715911
48.

Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice.

Carty N, Nash KR, Brownlow M, Cruite D, Wilcock D, Selenica ML, Lee DC, Gordon MN, Morgan D.

PLoS One. 2013;8(3):e59626. doi: 10.1371/journal.pone.0059626. Epub 2013 Mar 28.

49.

Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation.

Sudduth TL, Powell DK, Smith CD, Greenstein A, Wilcock DM.

J Cereb Blood Flow Metab. 2013 May;33(5):708-15. doi: 10.1038/jcbfm.2013.1. Epub 2013 Jan 30.

50.

Are inflammatory profiles the key to personalized Alzheimer's treatment?

Brothers HM, Wilcock DM.

Neurodegener Dis Manag. 2013;3(4):343-351.

Supplemental Content

Loading ...
Support Center